Proton Beam Therapy in the Reirradiation Setting of Brain and Base of Skull Tumour Recurrences

• Published in: Clinical oncology (Royal College of Radiologists (Great Britain)) Vol. 35; no. 10; pp. 673 - 681
• Main Authors: Gaito, S., Burnet, N.G., Aznar, M.C., Marvaso, G., Jereczek-Fossa, B.A., Crellin, A., Indelicato, D., Pan, S., Colaco, R., Rieu, R., Smith, E., Whitfield, G.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-10-2023
• Subjects: Base of skull; brain; proton therapy; reirradiation; salvage treatments; reirradiation; Base of skull; salvage treatments; proton therapy; brain
• ISSN: 0936-6555; 1433-2981
• DOI: 10.1016/j.clon.2023.07.010

The therapeutic management of local tumour recurrence after a first course of radical radiotherapy is always complex. Surgery and reirradiation carry increased morbidity due to radiation-induced tissue changes. Proton beam therapy (PBT) might be advantageous in the reirradiation setting, thanks to its distinct physical characteristics. Here we systematically reviewed the use of PBT in the management of recurrent central nervous system (CNS) and base of skull (BoS) tumours, as published in the literature. The research question was framed following the Population, Intervention, Comparison and Outcomes (PICO) criteria: the population of the study was cancer patients with local disease recurrence in the CNS or BoS; the intervention was radiation treatment with PBT; the outcomes of the study focused on the clinical outcomes of PBT in the reirradiation setting of local tumour recurrences of the CNS or BoS. The identification stage resulted in 222 records in Embase and 79 in Medline as of March 2023. Sixty-eight duplicates were excluded at this stage and 56 were excluded after screening as not relevant, not in English or not full-text articles. Twelve full-text articles were included in the review and are presented according to the site of disease, namely BoS, brain or both brain and BoS. This review showed that reirradiation of brain/BoS tumour recurrences with PBT can provide good local control with acceptable toxicity rates. However, reirradiation of tumour recurrences in the CNS or BoS setting needs to consider several factors that can increase the risk of toxicities. Therefore, patient selection is crucial. Randomised evidence is needed to select the best radiation modality in this group of patients.